RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://doi.org/10.1055/a-1562-7882 below:

Thieme E-Journals - DMW - Deutsche Medizinische Wochenschrift

Dtsch Med Wochenschr 2021; 146(24/25): 1613-1618
DOI: 10.1055/a-1562-7882

Amyotrophe Lateralsklerose (ALS) – Diagnose, Verlauf und neue BehandlungsoptionenAmyotrophic lateral sclerosis (ALS) – diagnosis, course of disease and treatment options
In Deutschland sind 6000–8000 Menschen an ALS erkrankt. Die ALS ist nicht heilbar, jedoch bestehen zahlreiche Behandlungsoptionen zur Lebensverlängerung, verbesserten Symptomkontrolle und zur sozialen Teilhabe. Die Behandlung von Menschen mit ALS ist ein Paradigma der interdisziplinären und multiprofessionellen Versorgung. Der Beitrag erinnert an Stephen Hawking, der im Januar 2022 seinen 80. Geburtstag feiern würde.
Abstract

Amyotrophic lateral sclerosis (ALS) is an adult-onset motor neuron disorder which is characterized by progressive motor symptoms, such as muscle weakness, muscle atrophy and spasticity. In Germany, 6000–8000 people are affected by ALS. Between 1200 and 1600 newly diagnosed patients are expected each year. Protein deposits in the cytoplasm of motor neurons are a molecular feature of ALS. The most common protein aggregates result from excessive deposition of TDP-43. Familial ALS is present in 5 to 10 % of all ALS patients. Common causal genes include C9orf72, SOD1, FUS, and TARDBP. Genetic factors may be involved even without a family history of ALS and may be underestimated. The disease course and progression are highly variable. Symptom severity and rate of progression are determined by the ALS Functional Scale (ALSFRS-R). Beyond clinical symptoms and the patient’s perception of disease burden, measurement of slow vital capacity (SVC), peak cough flow (PCF), and body mass index (BMI) are used to underscore the indications for ventilatory and nutritional interventions, as well as palliative care. The validity of the biomarker neurofilament light chain (NF-L) for estimating prognosis is currently being investigated. ALS is not curable – however, various individual treatment options have to be considered for improving survival, symptom control and social participation. The care in specialized ALS centers is recommended to ensure optimal treatment regarding symptomatic medication, assistive devices, nutrition support and ventilation therapy. Optimal care is achieved by interdisciplinary collaboration of general practitioners, specialized physicians, neurologists and ALS experts being integrated in multiprofessional care networks.

Schlüsselwörter

Amyotrophe Lateralsklerose (ALS) - Motoneuron - Proteinablagerung - TDP-43 - Neurofilament light Chain (NF-L) - spezialisierte Versorgung

Key words

amyotrophic lateral sclerosis (ALS) - motor neuron - protein deposition - TDP-43 - neurofilament light chain (NF-L) - specialized care

Publication History

Article published online:
08 December 2021

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Literatur
1 Rees M. Stephen Hawking (1942–2018) World-renowned physicist who defied the odds. Nature 2018; 555: 444
2 Hardiman O, Al-Chalabi A, Chio A. et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers 2017; 3: 17071
3 Brenner D, Weishaupt JH. Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol 2019; 32: 735-739
4 Pender N, Pinto-Grau M, Hardiman O. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol 2020; 33: 649-654
5 Leitlinie der Deutschen Gesellschaft für Neurologie zur Diagnostik und Behandlung der ALS. Im Internet (Stand: 13.11.2021): https://dgn.org/leitlinien/ll-18-2012-amyotrophe-lateralsklerose-motoneuronerkrankungen/
6 Talman P, Duong T, Vucic S. et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open 2016; 6: e012054
7 Spittel S, Maier A, Kettemann D. et al. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. Eur J Neurol 2021; 28: 1160-1171
8 Cedarbaum JM, Stambler N, Malta E. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21
9 Maier A, Holm T, Wicks P. et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation – a prospective trial. Amyotroph Lateral Scler 2012; 13: 210-216
10 Verde F, Otto M, Silani V. Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front Neurosci 2021; 15: 679199
11 Multi-zentrische Studie zum Biomarker NF-L-Studie bei der ALS. Im Internet (Stand: 13.11.2021): https://www.als-charite.de/aktuelle-studien/
12 ALS-Versorgungs- und Forschungsplattform Ambulanzpartner. Im Internet (Stand: 13.11.2021): https://www.ambulanzpartner.de/versorgungsnetzwerk/
13 ALS-Versorgungsnetzwerk Mecklenburg-Vorpommern. Im Internet (Stand: 13.11.2021): https://www.aerzteblatt.de/nachrichten/sw/Amyotrophe%20Lateralsklerose?s=&p=1&n=1&nid=123093
14 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591
15 Miller T, Cudkowicz M, Shaw PJ. et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2020; 383: 109-119
16 Brenner D, Freischmidt A, Ludolph AC. et al. Genspezifische Therapieansätze bei Amyotropher Lateralsklerose in Gegenwart und Zukunft. Nervenarzt 2020; 91: 287-293
17 Meyer T, Kettemann D, Maier A. et al. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. J Neurol Neurosurg Psychiatry 2020; 91: 783-785
18 Funke A, Spittel S, Grehl T. et al. Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19: 342-350
19 Dorst J, Ludolph AC, Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther Adv Neurol Disord 2017; 11: 1756285617734734
20 Ludolph AC, Dorst J, Dreyhaupt J. et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol 2020; 87: 206-216
21 Unterstützung der Versorgungsplanung durch eine ALS-zentrierte Patientenverfügung. Im Internet (Stand: 13.11.2021): https://www.als-charite.de/wp-content/uploads/2020/03/ALS-Ambulanz_Patientenverfuegung_V3_1_interaktiv_02_FINAL.pdf

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3